Research
Publication and reporting of clinical trial results: cross sectional analysis across academic medical centers
BMJ 2016; 352 doi: https://doi.org/10.1136/bmj.i637 (Published 17 February 2016) Cite this as: BMJ 2016;352:i637
Data supplement
Web extra
- Data Supplement - Supplemental appendix: additional information
Related articles
- Editorial Published: 24 May 2016; BMJ 353 doi:10.1136/bmj.i2770
- Research Published: 26 July 2017; BMJ 358 doi:10.1136/bmj.j3334
- Research Published: 24 May 2018; BMJ 361 doi:10.1136/bmj.k2031
- Research Published: 06 June 2018; BMJ 361 doi:10.1136/bmj.k2130
- Research Published: 12 September 2018; BMJ 362 doi:10.1136/bmj.k3218
See more
- Antiphospholipid syndrome: advances in diagnosis, pathogenesis, and managementBMJ February 27, 2023, 380 e069717; DOI: https://doi.org/10.1136/bmj-2021-069717
- Gender dysphoria in young people is rising—and so is professional disagreementBMJ February 23, 2023, 380 p382; DOI: https://doi.org/10.1136/bmj.p382
- US task force calls for hypertension screening in all pregnanciesBMJ February 13, 2023, 380 p347; DOI: https://doi.org/10.1136/bmj.p347
- Covid-19: FDA removes US authorisation for antibody drug EvusheldBMJ February 01, 2023, 380 p264; DOI: https://doi.org/10.1136/bmj.p264
- Covid-19: US will end public health emergency on 11 May, says BidenBMJ February 01, 2023, 380 p262; DOI: https://doi.org/10.1136/bmj.p262
Cited by...
- Results Availability and Timeliness of Registered COVID-19 Clinical Trials: A Cross-Sectional Study
- Ethical and practical considerations in HIV drug trial closure: perspectives of research staff in Uganda
- Facilitated transition in HIV drug trial closure: a conceptual model for HIV post-trial care
- Results dissemination of registered clinical trials across Polish academic institutions: a cross-sectional analysis
- Clinical trials of neurointervention : 2007-2018
- Commitments by the biopharmaceutical industry to clinical trial transparency: the evolving environment
- Results dissemination from clinical trials conducted at German university medical centres was delayed and incomplete
- Commitments by the Biopharmaceutical Industry to Clinical Trial Transparency: The Evolving Environment
- Postmarketing commitments for novel drugs and biologics approved by the US Food and Drug Administration: a cross-sectional analysis
- Research integrity and the law that never was
- Compliance with requirement to report results on the EU Clinical Trials Register: cohort study and web resource
- Clinical trial design and dissemination: comprehensive analysis of clinicaltrials.gov and PubMed data since 2005
- Postmarket studies required by the US Food and Drug Administration for new drugs and biologics approved between 2009 and 2012: cross sectional analysis
- Characteristics and publication fate of unregistered and retrospectively registered clinical trials submitted to The BMJ over 4 years
- Data Sharing and Cardiology: Platforms and Possibilities
- Measuring clinical trial transparency: an empirical analysis of newly approved drugs and large pharmaceutical companies
- Learning From Major Clinical Trials: Bending Without Breaking
- Time to publication for publicly funded clinical trials in Australia: an observational study
- Cross-sectional assessment of patient attitudes towards participation in clinical trials: does making results publicly available matter?
- Transforming Drug Development in Heart Failure: Navigating the Regulatory Crossroads
- Discontinuation and Nonpublication of Randomized Clinical Trials Conducted in Children
- Money back guarantees for non-reproducible results?